Back to Research

Organization profile

InSphero

InSphero is a global market leader in 3D in vitro models and organ-on-chip systems, providing highly scalable and reproducible human microtissues for non-animal drug testing. The company specializes in liver safety, metabolic diseases, and oncology, helping pharmaceutical organizations replace animal models with more predictive, human-relevant data.

Schlieren, SwitzerlandFounded 2009

Overview

1. Executive Summary (Confidence: High)

InSphero AG, founded in 2009 as a spin-off of ETH Zurich, is the industry standard-bearer for "The Model of Excellence™" in 3D cell culture. Headquartered in Schlieren, Switzerland, the organization provides a suite of advanced microphysiological systems that address the high failure rate of drugs in clinical trials. In November 2025, InSphero significantly expanded its technological moat by acquiring DOPPL SA and its Sun Bioscience Gri3D® technology, effectively merging the scalability of spheroids with the physiological depth of organoids. The company is at the vanguard of the longevity ecosystem, offering immune-competent models and specialized metabolic assays that accelerate the discovery of therapies for age-related conditions like fibrosis and Type 1 Diabetes. With a global distribution network and a laboratory hub in North America, InSphero is a critical partner for the modernization of drug discovery.

Unlock the full profileGet the complete company dossier

This public view only shows an extract. Open the full profile to access the complete company intelligence record, including the full write-up and structured research details.

Desktop only

Research is currently available on desktop only.

The Research module is designed for larger screens. Please reopen it on a desktop or laptop to use the screener, filters, detail pages, and admin tools.